Hexarelin

Hexarelin, also known as Examorelin or HEX, is a synthetic growth hormone-releasing hexapeptide classified as a Growth Hormone compound for research applications. This peptide operates through a well-defined mechanism involving the ghrelin receptor, also termed the growth hormone secretagogue receptor (GHSR). In research models, Hexarelin demonstrates its primary function by binding to GHSR, which initiates a cascade of intracellular events culminating in increased growth hormone secretion from the pituitary gland. Studies indicate that this growth hormone-releasing peptide exhibits multiple research effects beyond GH stimulation, including notable cardioprotective properties through modulation of cardiac function and reduction of myocardial fibrosis. Research data demonstrates that Hexarelin increases growth hormone levels whilst enhancing muscle-regulatory pathways and repair processes in laboratory studies. Additionally, investigations have shown improvements in cardiac function and reductions in myocardial fibrosis, suggesting potential cardiovascular research applications. Studies also indicate increases in bone mineral density in research models. The evidence grade for Hexarelin is classified as B, reflecting a limited but promising body of human trials primarily focused on growth hormone-releasing effects and cardiovascular benefits. These investigations have demonstrated encouraging results in elevating GH levels and improving cardiac function parameters. However, researchers note that more extensive clinical trials are required to fully characterise long-term safety profiles and efficacy in research applications. Hexarelin represents a valuable research tool for investigating growth hormone pathways and cardiovascular function, offering researchers a synthetic peptide with demonstrated effects on multiple physiological systems in laboratory studies.